Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Persistence of secukinumab and ixekizumab in psoriasis

Persistence of secukinumab and ixekizumab in psoriasis

Fernández-Villacañas Fernández, Pilar
Herreros Fernandez, Anabel

Paperback

Medical Reference

ISBN10: 6209386687
ISBN13: 9786209386688
Publisher: Our Knowledge Publishing
Published: Dec 3 2025
Pages: 60
Weight: 0.21
Height: 0.14 Width: 6.00 Depth: 9.00
Language: English
Psoriasis is a chronic, immune-mediated inflammatory disease that requires effective and sustained treatments. Interleukin 17 inhibitors, such as secukinumab and ixekizumab, have shown high efficacy in moderate-severe psoriasis, although there may be differences in their therapeutic persistence, understood as the time that a patient maintains treatment without discontinuing it. This observational, retrospective, single-center, longitudinal, retrospective study will compare the persistence of both drugs in patients seen between January 2017 and October 2024. Data will be obtained from medical records and pharmacy records. Kaplan-Meier curves and Cox regression models will be used to analyze persistence and associated factors. The results will generate local evidence on its effectiveness in real practice, contributing to personalize therapy and improve clinical decision making.

Also from

Fernández-Villacañas Fernández, Pilar

View All

Also in

Medical Reference

View All